Business Context and Reporting Period
This Form 8-K filing by Cognition Therapeutics, Inc. (CGTX) is dated March 12, 2025. The Company is an emerging growth company incorporated in Delaware. The report addresses a material event regarding the listing status of its common stock on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on regulatory compliance regarding stock listing requirements.
Material Changes and Events
- Listing Deficiency: The Company previously received notice that its closing bid price had been below the $1.00 minimum requirement for 30 consecutive business days.
- Extension Granted: On March 12, 2025, Nasdaq granted an additional 180 calendar days (until September 8, 2025) to regain compliance with the minimum bid price rule.
- Market Transfer: Effective March 14, 2025, the Company's common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market.
Outlook, Risks, and Management Commentary
Management intends to actively monitor the bid price and considers available options to resolve the deficiency, including a potential reverse stock split. To regain compliance, the stock must trade at or above $1.00 per share for 10 consecutive business days before September 8, 2025.
Risks and Contingencies:
- If compliance is not achieved by September 8, 2025, the stock will be subject to delisting.
- The Company may appeal a delisting determination to a Nasdaq Hearings Panel.
- There is no assurance that the Company will regain compliance or avoid delisting.
Investor Verification Checklist
- Verify the current closing bid price of CGTX stock relative to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes.
- Confirm the effective date of the transfer to the Nasdaq Capital Market (March 14, 2025).
- Track the deadline of September 8, 2025, for the final compliance determination.